Tag: CA

Platform-Disease Modifying Therapies

Efficacy and Safety of Ublituximab Versus Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase 3 Ultimate I and II Trials

Background: Ublituximab, a novel monoclonal antibody, targets a unique epitope on the CD20 antigen and is glycoengineered for enhanced...

Read More

Platform-Disease Management

Treating Minority Patients with Multiple Sclerosis: Development of the CHIMES Trial

Background: Black, African American (AA) and Hispanic/Latino (HA) patients with multiple sclerosis (MS) have greater disease severity and...

Read More

Platform-Psychosocial

Social-Cognitive Correlates of Physical Activity in Fatigued and Non-Fatigued Persons with Multiple Sclerosis

Background: There is interest in the application of behavioral interventions for increasing physical activity among adults with multiple...

Read More

Platform-Neuroimaging

A Description of Real-World MRI Acquired in Patients with Multiple Sclerosis: Preliminary Insights from FlywheelMS

Background: Magnetic resonance imaging (MRI) in the context of routine care is an important tool that can inform clinical decisions in...

Read More

Platform-Rehabilitation

Effects of weekly participation in a wellness program on people living with multiple sclerosis: a three-year analysis

Background: The Multiple Sclerosis Achievement Center (MSAC) conducts day wellness programs to address physical, cognitive and social...

Read More

Platform-Disease Modifying Therapies

Design of the Phase II, Double-Blind, Placebo-Controlled Dose-Expansion Portion of a Two-Part, Phase I/II, Multicenter Trial in Progressive Multiple Sclerosis

Background: Infection with Epstein-Barr virus (EBV) is a necessary risk factor for the development of multiple sclerosis (MS) Abrahamyan S...

Read More

Platform-Rehabilitation

Beyond the Physical Symptoms of Spasticity for Persons with MS Spasticity: Results from SEEN-MSS, a Large-Scale, Self-Reported Survey

Background: Spasticity, a complex and multi-dimensional symptom of multiple sclerosis (MS), occurs in up to 80% of those with MS. It is...

Read More

Platform-Neuroimaging

Improving the Utilization of Standardized Mris in Multiple Sclerosis Care: A Pragmatic Trial Perspective

Background: Magnetic resonance imaging (MRI) is a key part of the diagnosis and follow-up of people with multiple sclerosis (MS). However,...

Read More

Platform-Disease Modifying Therapies

Effectiveness, Safety and PROs of Ofatumumab in RMS Patients Switching from Dimethyl Fumarate or Fingolimod: Artios Phase 3b Study Design

Background: Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of adults with relapsing multiple...

Read More

Platform-Psychosocial

Health-Related Quality of Life across the Lifespan in Persons with Multiple Sclerosis and Healthy Controls

Background: Health-related quality of life (HRQOL) is reduced in persons with multiple sclerosis (MS) compared with the general population,...

Read More